Resmed’s stock falls by 7% on soft FY27 outlook
ResMed shares fell about 7% after the company forecast softer FY27 revenue due to suspended Astral ventilator sales, macro uncertainty, and inflation in electronic components and freight. ResMed reported FY26 revenue of about $5.65bn (+10% YoY) and Q4 revenue of $1.46bn (+9%). FY27 revenue guidance is $5.75bn to $5.85bn, below analysts’ $5.92bn, citing a $75m headwind from an FDA Class 1 recall.
How this was made
The 30-second read
Why it matters
The FDA recall led ResMed to suspend Astral ventilator sales and forecast a $75m FY27 headwind, lowering FY27 revenue guidance below analysts’ expectations. This is a direct fundamental reset that can drive further estimate revisions and volatility until the field safety corrective action timeline is clearer.
Market read
A recall-driven sales suspension and quantified FY27 headwind ($75m) are the core trading catalysts behind the reported ~7% drop.
What to watch
The guidance range is still relatively close to consensus ($5.92bn vs $5.75bn to $5.85bn), so the market may be over-discounting the duration of the Astral suspension versus the magnitude of the $75m headwind.
Background
ResMed released FY26 and Q4 FY26 results alongside a softer FY27 outlook, while addressing an FDA Class 1 recall for certain Astral 100 and Astral 150 ventilators.
Ticker impact
ResMed shares fell about 7% after guiding FY27 revenue to $5.75bn to $5.85bn, citing suspended Astral ventilator sales and a $75m headwind.
Bearish near term, with downside risk to FY27 estimates until corrective-action progress and any resumption timeline become clearer.
The article ties the guidance cut directly to FDA recall-related suspension and quantifies the headwind ($75m), which is a concrete earnings risk catalyst.
Market effects
Highlights regulatory and product-safety risk for medical device ventilator makers, potentially pressuring the group’s recall-risk premium.
Limited direct regional spillover; the catalyst is company-specific FDA action and company guidance.
Could affect global respiratory care supply planning and competitive dynamics if Astral sales remain suspended beyond FY27.
Counterpoint
The company reports no deaths and only five serious injuries as of June, so the revenue hit may be temporary if corrective actions restore sales quickly.
Key entities
- companyResMed
Sleep apnea and ventilator manufacturer guiding FY27 revenue lower due to FDA recall-related Astral sales suspension.
- regulatorUS Food and Drug Administration (FDA)
Issued a Class 1 recall notice in July for certain Astral ventilators due to a potential component leak and fail-safe risk.
- productAstral 100 and Astral 150
Ventilators subject to the FDA Class 1 recall; ResMed is suspending sales while corrective action is taken.
